1 / 42

Minimal Requirement for Concepts of Anemia

Minimal Requirement for Concepts of Anemia. 林建廷 Dec 12, 2009. Erythrocyte Development. EPO: 90% from kidney 10% from liver. Hemoglobin. Fe + protoporphyrin α2β2 ↓ ↓ heme + globin ↓

ull
Download Presentation

Minimal Requirement for Concepts of Anemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Minimal Requirement for Concepts of Anemia 林建廷 Dec 12, 2009

  2. Erythrocyte Development EPO: 90% from kidney 10% from liver

  3. Hemoglobin Fe + protoporphyrin α2β2 ↓ ↓ heme + globin ↓ Hb

  4. Two main approaches for anemia that are not mutually exclusive: 1. Kinetic approach 2. Morphological approach

  5. Kinetic approach of Anemia Production? Survival/ Destruction? The key test is the …..

  6. Reticulocyte Production Index— an estimate of marrow production relative to normal Hct • Corrected Ret= Ret(%) * 45 Corrected Ret RPI= Maturation index

  7. RPI (kinetic approach) • RPI are the most helpful: • extremely low (<0.1%) • AA/ PRCA are the first considerations • extremely high (>3%) • Blood loss/ hemorrhage • Hemolytic anemia (although 25% AIHA have normal RPI)

  8. MCV>115 Vit B12, Folate Drugs that impair DNA synthesis (AZT, chemotherapy, azathioprine) MDS MCV 100 - 115 Ditto Reticulocytosis Hypothyroidism Alcoholism/ liver dz Morphological Approach-1

  9. Normocytic (MCV 80-100) Anemia of chronic disease (ACD) Mixed deficiencies Renal failure BM dz (ex AA, MDS, MM…) Microcytic (MCV<80) Iron deficiency anemia Thalassemia Anemia of chronic disease (ACD, 30-40%) Sideroblastic anemia Pb intoxification Morphological Approach-2

  10. Iron and IDA

  11. Distribution of Iron in Adults

  12. Storage iron Circulating iron  RBC iron  Tissue iron

  13. Harrison’s Principles of Internal Medicine 15th Ed. 2001

  14. IDA Presentation Presentation Diagnosis Ferritin: low (N=20-300) Iron/TIBC <16% (N=~33%) BM iron stain • Progressive MCV ↘ • Progressive RBC ↘ • Typically high RDW • Typically high MCV/RBC • Typically mild PLT ↑

  15. Causes of IDA Increased iron requirement Inadequate iron supply Poor nutritional intake Malabsorption Gastrectomy (may also has Vit B12 deficiency) • Hypermenorrhea • GI blood loss– hemorrhoid, PUD, GI cancer, angiodysplasia • Factitious removal • Hemolysis • Hemodialysis • Hookworm infestation • Rapid growth of teenage • Pregnancy and lactation

  16. Iron Supply • Oral: usually 3 months to restore iron storage • Ferrum chewable (Fe 3+) 100mg/tab • Hematonic (Fe 2+) 50mg/tab • IV • Atofen (!! Risk of allergy and anaphylaxis—0.6%)

  17. Thalassemia

  18. Hb Gene Harrison’s Principles of Internal Medicine 15th Ed. 2001

  19. Thalassemia Presentation Presentation Diagnosis Exclude IDA Hb electrophoreis: Hb A2>3.5% or HbF>2%  β-thalassemia HbH(+)  α-thalassemia with ¾ defect (HbH dz) HbA2 and HbF: N  α-thalassemia with ¼ or 2/4 defect Gene diagnosis • Constant low MCV • Constant high RBC • Typically low RDW • Typically low MCV/RBC • Typically iron storage ↗

  20. Gene Level of Thalassemia in Taiwan • α-thalassemia: Prevalence 4% • --SEAα0 deletion • -α3.7 deletion • -α4.2 deletion • HbQS or HbCS • β-thalassemia: Prevalence 2% • Codon 41/42 TCTT deletion β0 • IVS II 654 C-> T point-mutation β0 • Codon 17 A-> T β0 • Promoter 28 A-> G β+ • HbE (Codon 26 G-> A) β+ • ??% α + β-thalassemia (Severity?)

  21. 優生學的理由 β –Major (終身輸血) Hb H disease (黃疸) Hydrops fetalis (死胎)

  22. Thalassemia Treatment • Mild: None • Severe: • Folic acid • RBC transfusions + iron chelators • Allo-SCT

  23. Comparison of Iron Chelators

  24. Deferasirox (Exjade) • Common adverse effect: • Cre elevation (40%), (ref. 14% in DFO) • Proteinuria (18%) • GI (abd pain, N/V, diarrhea, 10-15%) • Hepatitis (8%) • Headache (15%), skin rash (11%) • No agranulocytosis, neutropenia or arthralgia • Pregnancy safety: • FDA category B

  25. Megaloblastic Anemia

  26. Megaloblastic Anemia Presentation Presentation Diagnosis ??Schilling test Low Vit B12 or folic acid Vit B12: 270~400: empirical try Vit B12< 270: definite deficiency • High high MCV • Pancytopenia • Hypersegmented PMN • Typically high RPI, hemolysis (LDH ↗), indirect hyperbilirubinemia • Tinnitus or other neurological presentation • Vegetarism (奶, 蛋, 維他命) • Gastrectomy or Pernicious anemia

  27. Remember Pancytopenia • P: PNH • A: Asplatic anemia • N: Neoplasm/ Near neoplasm (including MDS) • C: Cirrhosis/ Connective tissue disease • Y: Vit B12/ Folic acid • T: Toxin/ Drug • O: Overwhelming sepsis (Hemophagocytic syndrome)/ Others

  28. Vit B12/Folate Deficiency Anemia Treatment • Vit B12 deficiency: • Vit B12 1 mg im qd *5 q1wk *4  q1m*3  q6m • R/I pernicious anemia (Anti-parietal Ab, anti-IF Ab and PES) • Thyroid dz • Gastric cancer • Folate deficiency: Improved diet, folic acid

  29. Usually rapid responseMost important F/U Reticulocyte, LDH Harrison’s Principles of Internal Medicine 15th Ed. 2001

  30. Hemolytic Anemia

  31. Is there hemolysis? • Damaged RBCs on smear • spherocytes (immune hemolysis, HS) • RBCs fragments (microangiopathic anemias) • Marrow response to hemolysis • polychromasia on smear • reticulocytosis • erythroid hyperplasia in marrow • Biochemical evidence of RBCs destruction • Indirect hyperbilirubinemia • increased LDH • decreased/absent haptoglobin

  32. Extravascular vs Intravascular hemolysis Extravascular Intravascular Test Hemolysis Hemolysis LD á áá bilirubin á á haptoglobin N to absent absent hemoglobinuria absent present free Hb in plasma absent present urine hemosiderin absent present

  33. An approach to hemolytic anemia Hemolytic anemia Immune Non-immune Congenital Acquired • Autoimmune • Alloimmune • Drug-induced • Defects of: • Membrane/ skeleton • (eg. Hereditary spherocytosis) • Enzymes • (eg. G6PD deficiency) • Hemoglobinopathy • PNH • Infections • sepsis • malaria • Mechanical • Prosthetic heart valve • Microangiopathic HA (TTP, HUS, DIC) • Hypersplenism

  34. AIHA and DAT reactions

  35. D/D of AIHA

  36. Hepcidin and Anemia of Chronic Disease

  37. D/D of ACD and IDA ACD may concurrently coexist with true iron deficiency (In this situation, iron/TIBC is more reliable than ferritin)

  38. ACDTreatment

More Related